Search Results

You are looking at 1 - 10 of 271 items for :

  • All content x
Clear All
Free access

Jennifer S ten Kulve, Dick J Veltman, Liselotte van Bloemendaal, Paul F C Groot, Henricus G Ruhé, Frederik Barkhof, Michaela Diamant, and Richard G Ijzerman

, Cummings 2013 ), except for glucagon-like peptide-1 (GLP1). GLP1 is a gut-derived hormone, mainly known for its glucose-lowering effects ( Kreymann et al. 1987 , Mojsov et al. 1987 ); however, numerous preclinical and clinical studies have shown that

Free access

Sayaka Akieda-Asai, Paul-Emile Poleni, Kazuya Hasegawa, and Yukari Date

( Bjorbaek & Kahn 2004 ). Leptin also inhibits AMP-activated protein kinase (AMPK) activity in the arcuate nucleus and in the paraventricular nucleus of the hypothalamus ( Minokoshi et al . 2004 ). Glucagon-like peptide-1 (GLP1), a gastrointestinal hormone

Open access

Alessandro Pocai

insulin. Recent work on understanding the physiological function of proglucagon-derived peptides has renewed interest in glucagon-based therapeutics. One of these peptides is glucagon-like peptide-1 (GLP1), which is secreted from the L cells of the

Free access

Zhengu Liu, Violeta Stanojevic, Luke J Brindamour, and Joel F Habener

-cells to produce and secrete insulin in response to nutrients (glucose) and shortens their life span ( Grattagliano et al . 2008 , Haas & Biddinger 2009 ). In this study, we report that a nonapeptide, GLP1(28–36)amide, consisting of the C-terminal domain

Free access

N M Whalley, L E Pritchard, D M Smith, and A White

-cells of the intestine with PC1 catalysing the cleavage to yield glucagon-like peptide (GLP)-1 and GLP-2 ( Fig. 1 a). Evidence suggests the tissue-specific processing is due to differential expression of PC1 ( Tucker et al . 1996 ) and PC2 ( Rouille et al

Free access

Bernardo Nuche-Berenguer, Daniel Lozano, Irene Gutiérrez-Rojas, Paola Moreno, María L Mariñoso, Pedro Esbrit, and María L Villanueva-Peñacarrillo

obese subjects ( Zhao et al . 2008 , Buizert et al . 2009 ). It has been reported that the anti-diabetic peptides glucagon-like peptide 1 (GLP-1) and exendin 1–39 amide (Ex-4) show beneficial effects in reducing cholesterol and triglycerides in

Restricted access

Weijuan Shao, Wenjuan Liu, Ping Liang, Zhuolun Song, Odisho Israel, Gerald J Prud’homme, Qinghua Wang, and Tianru Jin

homeostasis induced by high fat diet feeding ( Untereiner et al. 2019 ). Sitagliptin is a type 2 diabetes (T2D) therapeutic agent, which prevents degradation of native incretin hormones, including glucagon-like peptide-1 (GLP-1) and gastric inhibitory

Restricted access

Katrine Dahl Bjørnholm, Gro Klitgaard Povlsen, Maria Elm Ougaard, Charles Pyke, Günaj Rakipovski, Pernille Tveden-Nyborg, Jens Lykkesfeldt, and Gry Freja Skovsted

treatment with long acting GLP-1 receptor (GLP1R) agonists on renal ( Moreno et al. 2002 , Yu et al. 2003 , Bisgaard et al. 2016 , Mann et al. 2017 ) and cardiovascular disease ( Marso et al. 2016 a b ). GLP-1 is a gut derived peptide hormone

Free access

Guillaume Mabilleau, Marie Pereira, and Chantal Chenu

needed, to reach an HbA 1C level of 7% or less. Among the most prescribed drugs, the glucagon-like peptide-1 receptor agonists (GLP-1RAs) have recently attracted attention as Glp-1r -knockout animals, and GLP-1-supplemented animals exhibited

Free access

Christian Hölscher

Introduction The main hallmark of type 2 diabetes mellitus (T2DM) is insulin desensitisation. The discovery that the incretin hormone glucagon-like peptide 1 (GLP-1) facilitates insulin release during episodes of hyperglycaemia and has several